China Animal Husbandry Industry Co., Ltd.
CAHIC
CAHIC (China Animal Husbandry Industry Co., Ltd.) is China's state-owned backbone enterprise in the animal health sector, representing the country's largest domestically-controlled veterinary pharmaceutical platform. Founded in 1998 and headquartered in Beijing, China, CAHIC generated CNY 6.205 billion (~USD 860 million) in 2025 revenue, employing approximately 5,000 employees across multiple GMP manufacturing bases. With 2025 operating cash flow surging 175.89% to CNY 1.158 billion, CAHIC possesses extraordinary financial firepower for its strategic pivot from traditional livestock vaccines into the high-margin companion animal pharmaceutical market.
Strengths:
• State-Backed Financial Strength: CNY 1.158 billion in operating cash flow (up 175.89% YoY in 2025) provides ample capital for acquisitions and in-house companion animal product development
• API-to-Formulation Integration: Deep vertical integration from active pharmaceutical ingredients to finished vaccines and formulations, with multiple GMP-certified manufacturing bases
• Domestic Market Dominance: As China's state-owned animal health flagship, CAHIC controls significant market share in mandatory livestock vaccines and veterinary pharmaceuticals
• R&D Investment Scale: CNY 178 million in 2025 R&D expenditure, increasingly directed toward companion animal vaccines and therapeutics
• Regulatory Privilege: State-owned enterprise status provides preferential access to government procurement contracts and accelerated regulatory approvals in China
Weaknesses:
• Minimal Current Pet Portfolio: Companion animal products currently represent a negligible share of total revenue; the pivot to pet healthcare is aspirational rather than realized
• Livestock Cycle Dependency: Core revenue remains tied to volatile Chinese swine and poultry production cycles, with 2025 adjusted net profit declining 67.42% due to industry headwinds
• International Presence Gap: Operations remain overwhelmingly China-centric, with limited brand recognition or regulatory approvals in North American and European marketsRead MoreShow Less
Strengths:
• State-Backed Financial Strength: CNY 1.158 billion in operating cash flow (up 175.89% YoY in 2025) provides ample capital for acquisitions and in-house companion animal product development
• API-to-Formulation Integration: Deep vertical integration from active pharmaceutical ingredients to finished vaccines and formulations, with multiple GMP-certified manufacturing bases
• Domestic Market Dominance: As China's state-owned animal health flagship, CAHIC controls significant market share in mandatory livestock vaccines and veterinary pharmaceuticals
• R&D Investment Scale: CNY 178 million in 2025 R&D expenditure, increasingly directed toward companion animal vaccines and therapeutics
• Regulatory Privilege: State-owned enterprise status provides preferential access to government procurement contracts and accelerated regulatory approvals in China
Weaknesses:
• Minimal Current Pet Portfolio: Companion animal products currently represent a negligible share of total revenue; the pivot to pet healthcare is aspirational rather than realized
• Livestock Cycle Dependency: Core revenue remains tied to volatile Chinese swine and poultry production cycles, with 2025 adjusted net profit declining 67.42% due to industry headwinds
• International Presence Gap: Operations remain overwhelmingly China-centric, with limited brand recognition or regulatory approvals in North American and European markets
Listed market data
600195 · SSE · weeklyHistory →- Market cap
- $1 B
- Share price
- ≈ CNY 1.00
- 1Y change
- -13.9%
- Recent change
- +1.2%
- IPO price
- +106.5%
- Revenue (TTM)
- CNY$6.2 B (~USD$860 M, 2025)
10-22 → 10-23
CNY 6.28 · from 1999-01-07
Financial history
Full market history- 2026-10CNY 6.62$1 B-1.6%
- 2026-09CNY 6.73$1 B-1.5%
- 2026-08CNY 6.83$1 B+4.4%
- 2026-07CNY 6.54$1 B+10.8%
- 2026-06CNY 5.90$907 M-10.6%
- 2026-05CNY 6.60$1 B-12.2%
- 2026-04CNY 7.52$1.2 B+1.5%
- 2026-03CNY 7.41$1.1 B-9.4%
- 2026-02CNY 8.18$1.3 B+0.1%
- 2026-01CNY 8.17$1.3 B+3.8%
- 2025-12CNY 7.87$1.2 B+1.3%
- 2025-11CNY 7.77$1.2 B—
While historically focused on livestock vaccines and pharmaceutical raw materials categories 2.17 and 10.1, CAHIC is aggressively pivoting toward the companion animal market, leveraging its massive idle fermentation capacity and state-backed R&D funding CNY 178 million in 2025. The company generated an impressive CNY 1.158 billion in operating cash flow in 2025 up 175.89% YoY, providing ample firepower for acquisitions or in-house development in the high-margin pet pharmaceutical segment.
• Veterinary Vaccines: livestock mandatory vaccines / companion animal vaccines in development
• Active Pharmaceutical Ingredients: antibiotics / antiparasitics
• Feed Additives & Premixes
• Veterinary Chemical Drugs
• Diagnostic Reagents
Quick Facts
Headquarters
Beijing, China
Founded
1998
Employees
5,000
Revenue
CNY$6.2 B (~USD$860 M, 2025)
Market cap
$1 B
Factories
Multiple large-scale GMP manufacturing bases across China
Presence
China domestic market, expanding to international
Listing
SSE: 600195
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SSE: 600195 , CAHIC Official Website
Shanghai Stock Exchange — CAHIC (600195)
Wikipedia — CAHIC